Marco Meglio, Editor for NeurologyLive, has been with the team since October 2019. Follow him on Twitter @marcomeglio1 or email him at mmeglio@neurologylive.com
Combination of Aducanumab Infusion and Focused Ultrasound Accelerates Reduction of Amyloid-ß Plaques
October 27th 2023The use of focused ultrasound-mediated blood-brain barrier opening has the potential to advance neurotherapeutics in the treatment of Alzheimer disease and other progreesive neurological disorder impacted by that barrier.
Dihydroergotamine Safe in Chronic Migraine With Cardiovascular Risk
October 24th 2023Stratification of the cohort into low- and elevated-cardiovascular risk groups revealed no differences in cardiovascular adverse events with repetitive DHE; however, elevated-risk patients had higher mean arterial blood pressure.
An Inside Look at the 11th Annual Miami Neuroscience Symposium
October 23rd 2023Diego Torres-Russotto, MD, chair of neurology at Baptist Health Miami Neuroscience Institute, provided an overview of the upcoming 11th Annual Miami Neuroscience Symposium, a 3-day educational event held in early November.
NeuroVoices: Diana Gallagher, MD, on New Phase 2 FUSION Study of BTK Inhibitor BIIB091
October 18th 2023The head of Biogen’s MS and Immunology Department Unit provided an overview of FUSION, a currently recruiting study assessing the efficacy and safety of BIIB091 as a monotherapy and in combination with diroximel fumarate.
Incorporating Augmented Reality to Treat Parkinson Disease Gait Problems
October 15th 2023Jay Alberts, PhD, the Edward F. and Barbara A. Bell Endowed Chair at Cleveland Clinic, provided comment on a recently published randomized controlled trial assessing the therapeutic potential of an augmented reality program for postural instability and gait dysfunction in Parkinson disease.
FDA Lifts Clinical Hold on FREEDOM-DM1 Study of Antisense Agent PGN-EDODM1
October 14th 2023In preclinical data, treatment with PGN-EDODM reduced pathogenic nuclear foci by 54% per nuclei and liberated muscleblind like splicing regulator 1, resulting in a greater than 68% correction of downstream transcript missplicing events.